188 related articles for article (PubMed ID: 23735741)
1. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.
Bilodeau F; Bailey MD; Bhardwaj PK; Bordeleau J; Forgione P; Garneau M; Ghiro E; Gorys V; Halmos T; Jolicoeur ES; Leblanc M; Lemke CT; Naud J; O'Meara J; White PW; Llinàs-Brunet M
Bioorg Med Chem Lett; 2013 Jul; 23(14):4267-71. PubMed ID: 23735741
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel P2 substituted 4-biaryl proline inhibitors of hepatitis C virus NS3 serine protease.
Bailey MD; Halmos T; Lemke CT
Bioorg Med Chem Lett; 2013 Aug; 23(15):4436-40. PubMed ID: 23773864
[TBL] [Abstract][Full Text] [Related]
3. Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
Nair LG; Bogen S; Ruan S; Pan W; Pike R; Tong X; Cheng KC; Guo Z; Doll RJ; Njoroge FG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1689-92. PubMed ID: 20149655
[TBL] [Abstract][Full Text] [Related]
4. Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
Naud J; Lemke C; Goudreau N; Beaulieu E; White PD; Llinàs-Brunet M; Forgione P
Bioorg Med Chem Lett; 2008 Jun; 18(11):3400-4. PubMed ID: 18448339
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
[TBL] [Abstract][Full Text] [Related]
6. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
Perni RB; Chandorkar G; Cottrell KM; Gates CA; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao G; Schairer WC; Van Drie J; Wei Y
Bioorg Med Chem Lett; 2007 Jun; 17(12):3406-11. PubMed ID: 17482818
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
Wang AX; Chen J; Zhao Q; Sun LQ; Friborg J; Yu F; Hernandez D; Good AC; Klei HE; Rajamani R; Mosure K; Knipe JO; Li D; Zhu J; Levesque PC; McPhee F; Meanwell NA; Scola PM
Bioorg Med Chem Lett; 2017 Feb; 27(3):590-596. PubMed ID: 28011221
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
[TBL] [Abstract][Full Text] [Related]
12. Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
Ortqvist P; Gising J; Ehrenberg AE; Vema A; Borg A; Karlén A; Larhed M; Danielson UH; Sandström A
Bioorg Med Chem; 2010 Sep; 18(17):6512-25. PubMed ID: 20673728
[TBL] [Abstract][Full Text] [Related]
13. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA
Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
Slater MJ; Amphlett EM; Andrews DM; Bamborough P; Carey SJ; Johnson MR; Jones PS; Mills G; Parry NR; Somers DO; Stewart AJ; Skarzynski T
Org Lett; 2003 Nov; 5(24):4627-30. PubMed ID: 14627400
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
[TBL] [Abstract][Full Text] [Related]
16. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
Ortqvist P; Peterson SD; Kerblom E; Gossas T; Sabnis YA; Fransson R; Lindeberg G; Helena Danielson U; Karlén A; Sandström A
Bioorg Med Chem; 2007 Feb; 15(3):1448-74. PubMed ID: 17113777
[TBL] [Abstract][Full Text] [Related]
17. Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
Bailey MD; Bordeleau J; Garneau M; Leblanc M; Lemke CT; O'Meara J; White PW; Llinàs-Brunet M
Bioorg Med Chem Lett; 2013 Aug; 23(15):4447-52. PubMed ID: 23773863
[TBL] [Abstract][Full Text] [Related]
18. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ
Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.
Nilsson M; Belfrage AK; Lindström S; Wähling H; Lindquist C; Ayesa S; Kahnberg P; Pelcman M; Benkestock K; Agback T; Vrang L; Terelius Y; Wikström K; Hamelink E; Rydergård C; Edlund M; Eneroth A; Raboisson P; Lin TI; de Kock H; Wigerinck P; Simmen K; Samuelsson B; Rosenquist S
Bioorg Med Chem Lett; 2010 Jul; 20(14):4004-11. PubMed ID: 20541405
[TBL] [Abstract][Full Text] [Related]
20. The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.
Bennett F; Huang Y; Hendrata S; Lovey R; Bogen SL; Pan W; Guo Z; Prongay A; Chen KX; Arasappan A; Venkatraman S; Velazquez F; Nair L; Sannigrahi M; Tong X; Pichardo J; Cheng KC; Girijavallabhan VM; Saksena AK; Njoroge FG
Bioorg Med Chem Lett; 2010 Apr; 20(8):2617-21. PubMed ID: 20303756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
